Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis

Zhao, Shuang; He, Jin-Lan; Qiu, Zhi-Xin; Chen, Nian-Yong; Luo, Zhuang; Chen, Bo-Jiang; Li, Wei-Min

추천

검색

자료유형: 학술저널

저자정보: Zhao, Shuang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) He, Jin-Lan (Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Qiu, Zhi-Xin (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Chen, Nian-Yong (Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Luo, Zhuang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Chen, Bo-Jiang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) Li, Wei-Min (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제16호

발행연도: 2014.1

수록면: 6,761 - 6,766 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: CD44v6 (CD44 variant exon 6) is the chief CD44 variant isoform regulating tumor invasion, progression, and metastasis. The prognostic value of CD44v6 expression in non small cell lung cancer (NSCLC) has been evaluated in many studies, but the results have remained controversial. Thus, we performed a meta-analysis of currently available studies to investigate the prognostic value of CD44v6 expression in NSCLC patients and the relationship between the expression of CD44v6 and clinicopathological features. Materials and Methods: Two independent reviewers searched the relevant literature in Pubmed, Medline and Embase from 1946 to January 2014. Overall survival (OS) and various clinicopathological features were collected from included studies. This meta-analysis was accomplished using STATA 12.0 and Revman 5.2 software. Pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated to estimate the effects. Results: A total of 921 NSCLC patients from ten studies met the inclusion criteria. The results showed that CD44v6 high expression was a prognostic factor for poor survival (HR=1.91, 95%CI=1.12-3.26, p<0.05). With respect to clinicopathological features, CD44v6 high expression was related to histopathologic type (squamous cell carcinoma versus adenocarcinoma: OR=2.72, 95%CI=1.38-5.38, p=0.004), and lymph node metastasis (OR=3.02, 95%CI=1.93-4.72, p<0.00001). Conclusions: Our results suggested CD44v6 high expression as a poor prognostic factor for NSCLC, and CD44v6 expression is associated with lymph node metastasis and histopathologic type. Therefore, CD44v6 expression can be used as a novel prognostic marker in NSCLC cases.

#CD44 variant exon 6 #non-small cell lung cancer #overall survival #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요